Highlights for 2017

A summary of our latest Annual Report and Accounts to showcase Vectura's key highlights over the past financial year

Latest news

Vectura on twitter

case studies

Our uniquely integrated formulation, device and development capabilities allow us to deliver the most complex products.

We take products from a blank piece of paper right the way through to market, but the patient is always at the centre of what we do
Breelib™ highlights our integrated development capabilities which enable us to support the development of complex inhaled products throughout the development lifecycle, from initial partner interaction, right down to product launch support and digital solution development.
Given the inherent complexity associated with developing inhaled generics, we believe that there are only a handful of companies which have the necessary capabilities to successfully develop these programmes.